Oncogenic HPV Types Infection in Adolescents and University Women from North Portugal: From Self-Sampling to Cancer Prevention
Table 2
Distribution of HPV in sexually active women.
HPV positive (%)
HPV HRa (%)
HPV pHRb (%)
HPV LRc (%)
HPV URd (%)
INCe (%)
Total ()
46 (16.6)
19 (41.3)
7 (15.2)
8 (17.4)
7 (15.2)
5 (10.9)
Age ()
≤17 ()
8 (7.5)
6/8 (75.0)
—
—
1/8 (12.5)
1/8 (12.5)
18–20 ()
19 (18.3)
6/19 (31.6)
3/19 (15.8)
3/19 (15.8)
4/19 (21.0)
3/19 (15.8)
>20 ()
19 (28.8)
7/19 (36.9)
4/19 (21.1)
5/19 (26.3)
2/19 (10.5)
1/19 (5.3)
≤17 ()
8 (7.5)
6/8 (75.0)
—
—
1/8 (12.5)
1/8 (12.5)
>17 ()
38 (22.4)
13/38 (34.2)
7/38 (18.4)
8/38 (21.1)
6/38 (15.8)
4/38 (10.5)
Age at first menarche ()
≤12 ()
26 (17.2)
9/26 (34.6)
5/26 (19.2)
4/26 (15.4)
5/26 (19.2)
3/26 (11.5)
>12 ()
20 (16.1)
10/20 (50.0)
2/20 (10.0)
4/20 (20.0)
2/20 (10.0)
2/20 (10.0)
Age at first sexual intercourse ()
≤16 ()
22 (15.4)
10/22 (45.4)
4/22 (18.2)
2/22 (9.1)
4/22 (18.2)
2/22 (9.1)
>16 ()
24 (18.8)
9/24 (37.5)
3/24 (12.5)
6/24 (25.0)
3/24 (12.5)
3/24 (12.5)
No. of Sexual partners ()
1 ()
15 (8.6)
8/15 (53.3)
1/15 (6.7)
2/15 (13.3)
3/15 (20.0)
1/15 (6.7)
2–5 ()
28 (29.8)
10/28 (35.7)
4/28 (14.3)
6/28 (21.4)
4/28 (14.3)
4/28 (14.3)
No. of years after first sexual intercourse ()
≤2 ()
23 (12.7)
11/23 (47.9)
2/23 (8.7)
3/23 (13.0)
3/23 (13.0)
4/23 (17.4)
>2 ()
23 (25.6)
8/23 (34.8)
5/23 (21.7)
5/23 (21.7)
4/23 (17.4)
1/23 (4.3)
Education level ()
Nonuniversity ()
23 (12.8)
11/23 (47.9)
4/23 (17.4)
1/23 (4.3)
2/23 (8.7)
5/23 (21.7)
University ()
23 (24.0)
8/23 (34.8)
3/23 (13.0)
7/23 (30.5)
5/23 (21.7)
—
HPV vaccination ()
No ()
34 (22.1)
13/34 (38.2)
7/34 (20.6)
7/34 (20.6)
4/34 (11.8)
3/34 (8.8)
Yes ()
9 (9.3)
5/9 (55.6)
—
—
3/9 (33.3)
1/9 (11.1)
aHigh-risk HPV; bProbable high-risk HPV; cLow-risk HPV; dUndeterminated- risk HPV; eInconclusive. The frequencies represented in the bold values of the table refer only to HPV-positives cases.
